Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivritasin Sodium for Prevention of ARDS in Children With Severe Pneumonia
ChiCTR2600121443Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sivritasin sodium in pneumonia and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Incidence of ARDS within 7 days after enrollment. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
sivritasin sodium
03
Conditions
pneumoniaacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2600121443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121443.